Full-Time
Senior Medical Director
Posted on 5/24/2025
4D Molecular Therapeutics
201-500 employees
Develops gene therapies using AAV vectors
Compensation Overview
$315k - $390k/yr
United States
In Person
 Medical, Clinical & Veterinary (1) |
|---|
- Medical Degree (M.D.)
- Residency training in Ophthalmology with a preference for subspecialty training in retina
- 8+ years of clinical ophthalmology research in the biopharmaceutical industry
- Experience with Phase 3 retina clinical trials
- Experience writing clinical research protocols and acting as a medical monitor
- Travel: 15% (3 days/month)
- Knowledge of ICH-Good Clinical Practice and U.S. Food and Drug Administration regulatory guidelines
- Effective written and verbal communication skills, including public speaking
- Provides clinical leadership to multidisciplinary study execution teams drawn from clinical operations, clinical science, biometrics, regulatory affairs, CMC, pharm/tox, drug safety, commercial, and alliance partners
- Has lead accountability on the study teams for delivery of study protocols, study conduct, and study readouts
- Organizes and leads scientific advisory board meetings. Interacts with external experts and stakeholders to gather input.
- Serves as medical monitor on clinical studies.
- Serves as the primary clinical author of development plans, study protocols, amendments, ICFs, IBs, INDs, annual reports, CSRs, regulatory submissions / correspondence, and project-related documents. Accountable for the accuracy of all medical content of such documents.
- Works with the research organization and the portfolio management team to identify and support new project opportunities.
- Collaborates to identify program risks, and to create and implement mitigation strategies
- Other duties as assigned
- Board certification a plus
- Retina fellowship training a plus
- Experience with gene therapy a plus
- Experience with NDA/BLA/MAA submission a plus
- Experience in other phases (Phase 1, 2, 4) of clinical research a plus
- Knowledge of international regulatory guidelines a plus
4D Molecular Therapeutics develops gene therapies using its Therapeutic Vector Evolution platform to create adeno-associated virus (AAV) delivery vectors that transport therapeutic genes to patients’ cells. This clinical-stage biotech focuses on genetic diseases such as cystic fibrosis, delivering genetic material through engineered AAV vectors in targeted tissues. Its product approach involves R&D and clinical trials to test safety and efficacy, followed by commercialization through direct sales or partnerships with larger pharmaceutical companies. The company differentiates itself with a proprietary vector evolution technology that enables tailored, precise gene delivery and by pursuing funding and collaborations (e.g., with the Cystic Fibrosis Foundation) to advance therapies like 4D-710. The goal is to bring gene therapies to market to treat serious genetic diseases and improve patient outcomes, funded by equity investments, strategic partnerships, and future product sales.
Company Size
201-500
Company Stage
IPO
Headquarters
Emeryville, California
Founded
2013
Simplify's Take
What believers are saying
- 4FRONT-1 Phase 3 randomization completes March 2026; topline H1 2027.
- Otsuka deal yields $85M upfront, $336M milestones for APAC 4D-150.
- $457.6M cash lasts to 2028, funding 4FRONT-2 enrollment H2 2026.
What critics are saying
- Vertex modulators capture 95% CF patients, slashing 4D-710 market by 2027.
- Regenxbio RGX-314 outperforms 4D-150 durability in wet AMD Phase 3 trials.
- 91% revenue drop to $15M in 2026 burns cash, forces dilution by end-2026.
What makes 4D Molecular Therapeutics unique
- Therapeutic Vector Evolution creates customized AAV vectors like R100 for intravitreal delivery.
- 4D-150 delivers multi-year anti-VEGF via single injection for wet AMD.
- 4D-710 achieves aerosol CFTR expression in CF lungs post-Phase 1/2.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 5%4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. 4D Molecular Therapeutics, Inc. announced a leadership change in its finance function. On March 25, 2026, the Board appointed Kristian Humer as the company's Principal Accounting Officer, effective immediately. He will hold this role in addition to serving as Chief Financial Officer and Principal Financial Officer. Humer succeeds Ashoo Gupta in the Principal Accounting Officer role; Gupta remains Vice President, Finance and Controller. The filing highlights Humer's prior experience as CFO at Foghorn Therapeutics and Viridian Therapeutics and his earlier senior investment banking roles at Citigroup focused on healthcare. 8-K event classification. Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Key figures. Appointment date: March 25, 2026 Age of appointee: 51 years Key terms. Principal Accounting Officer, Principal Financial Officer, Emerging growth company, Item 5.02, +1 more 03/30/2026 - 05:29 PM Faq. What leadership change did 4D Molecular Therapeutics (FDMT) disclose in this 8-K? 4D Molecular Therapeutics disclosed that its Board appointed Kristian Humer as Principal Accounting Officer effective March 25, 2026. He already serves as Chief Financial Officer and Principal Financial Officer, consolidating key finance and accounting responsibilities under a single executive leader. Who is replacing whom as Principal Accounting Officer at 4D Molecular Therapeutics (FDMT)? Kristian Humer is replacing Ashoo Gupta as Principal Accounting Officer at 4D Molecular Therapeutics. Gupta will continue with the company in her existing position as Vice President, Finance and Controller, maintaining continuity in the broader finance organization while shifting the designated accounting officer role. What is Kristian Humer's current role at 4D Molecular Therapeutics (FDMT)? Kristian Humer serves as Chief Financial Officer and Principal Financial Officer and has now been appointed Principal Accounting Officer. This means he oversees the company's overall financial management and is also designated as the primary officer responsible for accounting oversight and related SEC reporting functions. What prior experience does Kristian Humer bring to 4D Molecular Therapeutics (FDMT)? Kristian Humer previously served as Chief Financial Officer at Foghorn Therapeutics and as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics. Before those roles, he spent over a decade at Citigroup Global Markets, most recently as Managing Director in the Healthcare Investment Banking Group. When did the Board of 4D Molecular Therapeutics (FDMT) approve this officer change? The Board of 4D Molecular Therapeutics approved the appointment of Kristian Humer as Principal Accounting Officer on March 25, 2026. The change was effective immediately as of that date, and the company later recorded the event in its current report signed by President and Chief Executive Officer David Kirn. Does Ashoo Gupta remain with 4D Molecular Therapeutics (FDMT) after this change? Yes. Although Ashoo Gupta is no longer designated as Principal Accounting Officer, she continues as Vice President, Finance and Controller. This preserves leadership continuity in the finance team while reassigning the formal Principal Accounting Officer title to Chief Financial Officer and Principal Financial Officer Kristian Humer. Filing exhibits & attachments. 1 document
Sam Moskowitz MD appointed as Senior Vice President, Therapeutic Area Head, Lung at 4DMT. Congratulations to its client 4D Molecular Therapeutics for appointing Sam Moskowitz MD as Senior Vice President, Therapeutic Area Head, Lung. 4DMT is a leading late-stage biotechnology company developing durable, disease-targeted therapeutics with the potential to transform treatment paradigms and deliver unprecedented patient benefits. Its lead product candidate, 4D-150, is designed as a backbone therapy for blinding retinal vascular diseases, providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) through a single intravitreal injection, significantly reducing the treatment burden of current bolus injections. The lead indication for 4D-150 is wet age-related macular degeneration, now in Phase 3, with diabetic macular edema as a second indication. The Company's second product candidate, 4D-710, is the first known genetic medicine to achieve successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics(TM), 4DMT(TM), Therapeutic Vector Evolution(TM), and the 4DMT logo are trademarks of 4DMT. C1 Team: Christos Richards, Jed Donnelly, Evan Fishel, Leo Cain, & Todd Aghazadeh
Kristian F. Humer appointed as Chief Financial Officer at 4DMT. Congratulations to its client 4D Molecular Therapeutics for appointing Kristian F. Humer as Chief Financial Officer. 4DMT is a leading late-stage biotechnology company developing durable, disease-targeted therapeutics with the potential to transform treatment paradigms and deliver unprecedented patient benefits. Its lead product candidate, 4D-150, is designed as a backbone therapy for blinding retinal vascular diseases, providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) through a single intravitreal injection, significantly reducing the treatment burden of current bolus injections. The lead indication for 4D-150 is wet age-related macular degeneration, now in Phase 3, with diabetic macular edema as a second indication. The Company's second product candidate, 4D-710, is the first known genetic medicine to achieve successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics(TM), 4DMT(TM), Therapeutic Vector Evolution(TM), and the 4DMT logo are trademarks of 4DMT. C1 Team: Christos Richards & Leo Cain
4DMT and Otsuka Pharmaceutical partner on 4D-150 in the greater Asia-Pacific region. Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets. 4D Molecular Therapeutics (4DMT) announced a strategic partnership with Otsuka Pharmaceutical to develop and commercialize 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and in the greater Asia-Pacific (APAC) region, including Japan. According to the company, under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets. Additionally, Otsuka will lead all regulatory and commercialization activities in its licensed territories. 4DMT will receive an upfront cash payment of $85 million as well as expected cost sharing of at least $50 million over the next 3 years for global development activities and is eligible for up to $336 million in potential regulatory and commercial milestone payments. 4DMT will retain full development and commercialization rights for 4D-150 outside the APAC region, including the US, Latin America, and Europe. 4D-150 is an investigational agent designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection. It utilizes the company's customized and evolved intravitreal vector, R100. Recently, the company announced positive results from the SPECTRA clinical trial evaluating 4D-150 in patients with DME. The study enrolled 22 patients across 3 dose levels, including the phase 3 dose of 3E10 vg/eye (n=9) and supplemental doses of 1E10 vg/eye (n=12) and 5E9 vg/eye (n=1). It was noted that 2 patients dosed in the 1E10 vg/eye missed over 50% of study visits and were considered not evaluable for injection burden or other efficacy parameters. According to the data, 4D-150 is well-tolerated with no intraocular inflammation at any timepoint over 60 weeks. Additionally, no patients required any modification to the topical corticosteroid regimen. David Kirn, MD, co-founder and CEO of 4DMT, as well as Makoto Inoue, president and representative director of Otsuka Pharmaceutical, commented on the partnership in a press release. "We are thrilled to announce this strategic partnership with Otsuka, a leading global pharmaceutical company with a strong presence in the APAC region, reflecting our shared long-term commitment to improving outcomes for patients with retinal vascular diseases," said Kirn. "This partnership is a key pillar of our global strategy, with 4DMT continuing to lead Phase 3 clinical trial and manufacturing activities globally, in addition to pre-commercial and commercial activities outside the APAC region." "Otsuka has created new value that contributes to the well-being of patients in Japan and around the world through both in-house and collaborative research. By introducing 4D-150 to the markets in Japan and elsewhere in Asia and Oceania, we aim to help prevent vision loss through a single, potentially lifelong administration," added Inoue. * 4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific. Published October 30 2025. Accessed November 3, 2025. * 4DMT announces positive results from SPECTRA trial evaluating 4D-150 in patients with DME. Published August 4, 2025. Accessed November 3, 2025. Don't miss out - get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
4D Molecular Therapeutics has entered into a deal with Japan's Otsuka Pharmaceutical, granting them exclusive rights to develop and commercialize the gene therapy 4D-150 in Asia-Pacific markets. This agreement secures $85 million upfront to support 4DMT's Phase III program for treating wet age-related macular degeneration and diabetic macular edema.